AMN vs IART
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.
IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.
Compare Another Pair
Related Comparisons
AMN vs IART: Head-to-Head Comparison
This page compares AMN Healthcare Services, Inc. (AMN) and Integra LifeSciences Holdings Corporation (IART) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.